Cancer Stem Cells Connecting to Immunotherapy: Key Insights, Challenges, and Potential Treatment Opportunities
- PMID: 40647402
- PMCID: PMC12248597
- DOI: 10.3390/cancers17132100
Cancer Stem Cells Connecting to Immunotherapy: Key Insights, Challenges, and Potential Treatment Opportunities
Abstract
Cancer continues to pose a significant challenge to global health, resulting in millions of deaths annually despite advancements in treatments like surgery, chemotherapy, and radiotherapy. A key factor complicating successful outcomes is the presence of cancer stem cells (CSCs), which possess distinctive features that facilitate tumor initiation and progression as well as resistance to therapies. These cells are adept at evading conventional treatments and can hinder the effectiveness of immunotherapy, often manipulating the tumor microenvironment to suppress immune responses. This review delves into the complex interplay between CSCs and immune cells, emphasizing their contributions to tumor heterogeneity and therapeutic resistance. By investigating the CSC niche in which these cells thrive and their complex interactions with the immune system, we aim to reveal new therapeutic avenues that could enhance patient outcomes and minimize the risk of recurrence. CSCs are characterized by remarkable self-renewal and plasticity, allowing them to transition between stem-like and differentiated states in response to various stimuli. Their existence within the CSC niche confers immune protection and maintains stem-like properties while promoting immune evasion. Activating key signaling pathways and specific surface markers is crucial in developing CSC traits, pointing to potential strategies for effective tumor eradication. Conventional therapies often fail to eliminate CSCs, which can lead to tumor recurrence. Therefore, innovative immunotherapeutic strategies such as dendritic cell vaccines (DC vaccines), chimeric antigen receptor (CAR) engineered T cells, and immune checkpoint inhibitors (ICIs) are under examination. This review sheds light on CSC's roles across different malignancies, highlighting the necessity for innovative targeted approaches in cancer treatment.
Keywords: CSC niche; cancer stem cells (CSCs); immune evasion; immunotherapy; tumor microenvironment (TME).
Conflict of interest statement
The authors declare no conflicts of interest.
Figures





Similar articles
-
Oncolytic reovirus enhances the effect of CEA immunotherapy when combined with PD1-PDL1 inhibitor in a colorectal cancer model.Immunotherapy. 2025 Apr;17(6):425-435. doi: 10.1080/1750743X.2025.2501926. Epub 2025 May 12. Immunotherapy. 2025. PMID: 40353308
-
B cell antigens: A key to optimizing CAR-T cell therapy.Int Rev Immunol. 2025 Jun 19:1-28. doi: 10.1080/08830185.2025.2515839. Online ahead of print. Int Rev Immunol. 2025. PMID: 40537997 Review.
-
Management of urinary stones by experts in stone disease (ESD 2025).Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085. Epub 2025 Jun 30. Arch Ital Urol Androl. 2025. PMID: 40583613 Review.
-
An update on cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer.Future Oncol. 2025 Mar;21(6):715-735. doi: 10.1080/14796694.2025.2461443. Epub 2025 Feb 12. Future Oncol. 2025. PMID: 39936282 Review.
-
Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.Int J Mol Sci. 2023 Oct 10;24(20):15037. doi: 10.3390/ijms242015037. Int J Mol Sci. 2023. PMID: 37894718 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources